The difficulties in managing multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are well known. The regimens are very expensive, often toxic, and require up to 24 months to achieve an acceptable probability of success [1] [2] [3] .
No countrywide information in this sense is available from Latin America. As part of an ongoing collaboration project between the European Respiratory Society (ERS), the Brazilian Society of Respiratory Medicine (SBPT) and the Brazilian National TB Programme, we analysed the information provided by the Brazilian national register (SITE TB Q1 ¶ ), including all patients needing a treatment different from the standard 6 month regimen for (drug-susceptible) TB cases.
The aim of this study is to describe the resistance profile of the drugs composing the "shorter" regimen among MDR-TB cases diagnosed between 2000 and 2015.
In Brazil, the MDR-TB regimen is standardised in the majority of cases [13] . Originally, it contained clofazimine and ofloxacin, but in 2006 pyrazinamide replaced clofazimine and in 2010 levofloxacin replaced ofloxacin as the backbone fluoroquinolone (5 months with amikacin or streptomycin (five times a week for 1 month and three times a week for the following 4 months), ethambutol, levofloxacin, pyrazinamide and terizidone, and 12 months with ethambutol, levofloxacin and terizidone). Absolute frequencies ( percentages) and medians (interquartile ranges; IQRs) were used to describe qualitative and quantitative variables. Point and interval (95% CI) estimates were adopted to assess the drug resistance prevalence. Chi-squared or Fisher exact and Mann-Whitney tests were carried out to assess statistically significant differences for qualitative and quantitative variables, when appropriate. A p-value of less than 0.05 was considered statistically significant. All statistical analyses were performed using STATA version 14 (StataCorp LP 2015; College Station, TX, USA).
Of 6833 patients enrolled, 4477 (66%) were males, with a median (IQR) age of 39 (29-49) Drug susceptibility testing (DST) was performed using solid media (Lowenstein-Jensen, Middlebrook 7H10/11) until 2010, and then liquid media (Mycobacterial Growth Indicator Tube (MGIT™); BD Diagnostic, Sparks, MD, USA) in quality-assured laboratories.
In Brazil, DST is usually carried out for pyrazinamide and ethambutol. In the period 2000-2010, ethionamide was tested frequently, while in the period 2011-2015 the number of patients tested for this drug was lower, as well as the number of those tested for pyrazinamide. In the first period, fluoroquinolones and injectables were tested in a few patients (100 and 115, respectively), but in the period 2011-2015 DST was performed for these drugs more frequently. DST was not performed for clofazimine.
Overall, a high prevalence of drug resistance was found for pyrazinamide ( Comparing the periods 2000-2010 and 2011-2015, the prevalence of drug resistance decreased for all drugs, with a significant decline for pyrazinamide (51.5% versus 46.7%; p=0.01), ethambutol (37.9% versus 28.3%; p<0.0001) and ethionamide (29.7% versus 19.1%; p=0.01). The prevalence of resistance to fluoroquinolones increased from 30% to 34.9%, without any statistical significance (probably due to increased DST frequency).
The individual DST pattern was somehow heterogeneous during the entire study period (table 1) .
Focusing on the drugs composing the "shorter" regimen, in the period 2000-2010, of the 1319 MDR-TB patients undergoing DST for pyrazinamide, ethambutol and ethionamide, 150 (11.4%) were resistant to three drugs. Although the proportion of cases tested was low (table 1), resistance to fluoroquinolones was 30% (largely reflecting the DST for ofloxacin, which was performed on 28 of 100 strains tested for fluoroquinolones), 22.2% for kanamycin and 15.9% for amikacin.
In the period 2011-2015, the prevalence of resistance was 46.7% for pyrazinamide, 28.3% for ethambutol, 34.9% for fluoroquinolones (339/972, again largely reflecting the DST for ofloxacin), 12.6% for amikacin (120/951) and 11.6% for kanamycin (106/914).
The study has several limitations, because it is based on programmatic information in a setting where it is not possible to perform a complete DST for each patient. Furthermore, although performed in quality-controlled laboratories belonging to the WHO network, the reliability of DST for some of the drugs tested (pyrazinamide and ethionamide, among others) requires some caution in evaluating the data. Finally, we cannot exclude a selection bias related to the limited DST coverage for some of the drugs.
However, the database is quality-controlled and contains a large number of comprehensive nationwide records (over 6000 cases) from a high-TB-burden country. To our knowledge, this is the first nationwide report on the drug resistance profile of the drugs composing the WHO "shorter" regimen in a high-burden country.
The study results allow us to draw some important conclusions.
First, that the programmatic approach to MDR-TB through standardised regimens seems not to have contributed to increasing the prevalence of resistance to the drugs used [13] .
Secondly, although the data available in Brazil do not allow us to exactly predict the proportion of patients who are eligible for the shorter regimen, it is very likely to be higher than that recently reported in Europe (10%) and Pakistan (50%) [9] [10] [11] [12] . Considering that i) about 30% of the cases tested for fluoroquinolones are resistant to it, ii) recently, about 12% of patients were found to be resistant to second-line injectables (although not all Mycobacterium tuberculosis strains were tested for fluoroquinolones and second-line injectables), and iii) there is apparently no increase in resistance trend, we might optimistically assume that up to 50-55% of the MDR-TB population in Brazil is likely to be susceptible to both fluoroquinolones and injectables and, therefore, potentially suitable for the "shorter" regimen. It is, therefore, mandatory that susceptibility to the drugs composing the regimen is confirmed before prescribing it.
A recent study demonstrated that the "shorter" regimen might reduce, in 8 years, the MDR-TB incidence by between −23% and −2% based on several assumptions, including the long-term efficacy of the "shorter" regimen, the degree of scale-up of MDR-TB treatment, and the likely transmission of M. tuberculosis drug-resistant strains within the community [14, 15] . The results of this study Q2 ¶ contribute to complement the available evidence.
Thirdly, in agreement with the WHO recommendations [8] , it is important that national TB programmes in countries such as Brazil expand their capacity for rapid molecular testing (MTBDRsl) and DST for second-line drugs (at least fluoroquinolones and injectables) to enable clinicians to prescribe the "shorter" regimen to the right patients.
